|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00570 TRAD CHI MED
Nominal 
1.790 -0.010 (-0.556%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 14,744,779 | -10.690% | 16,509,708 | 18,121,861 | 14,304,242 | 19,052,802 |
| Cost of Sales | (7,653,651) | -11.553% | (8,653,400) | (8,847,369) | (7,105,790) | (7,223,639) |
| Gross Profit | 7,091,128 | -9.740% | 7,856,308 | 9,274,492 | 7,198,452 | 11,829,163 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (212,566) | 99.491% | (106,554) | (9,366) | (10,073) | (13,879) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (197) | -79.263% | (950) | (3,699) | (3,479) | (10,749) | |
| Profit / (Loss) before Taxation | (368,229) | -- | 163,109 | 1,224,533 | 840,109 | 2,520,280 | |
| Taxation | (89,860) | -36.869% | (142,338) | 171,537 | (119,144) | (396,856) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 116,019 | 248.447% | 33,296 | (110,870) | 43,521 | (190,566) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (342,070) | -- | 54,067 | 1,285,200 | 764,486 | 1,932,858 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 64,476 | -47.944% | 123,858 | 133,788 | 153,426 | 159,453 |
| Depreciation & Amortisation | 1,158,866 | 2.534% | 1,130,224 | 1,133,271 | 1,099,397 | 849,597 |
| Directors' Emoluments | 3,767 | -14.425% | 4,402 | 8,932 | 8,971 | 8,003 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -6.790 | -- | 1.070 | 25.520 | 15.180 | 38.380 |
| DPS (cts) | 0.000 | -- | 7.980 | 0.000 | 4.550 | 11.520 |
| Dividend Payout Ratio (%) | -- | -- | 745.794% | -- | 29.974% | 30.016% |
| Cash flow per share ($) | -- | -- | 0.513 | 0.232 | 0.217 | 0.158 |
| NBV per share ($) | 4.065 | -- | 4.211 | 4.202 | 4.005 | 3.916 |
| Remarks: | Real time quote last updated: 26/03/2026 17:34 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -342,070 |
| %Change | -- |
| EPS / (LPS) | RMB -0.068 |
| NBV Per Share (¥) | RMB 4.065 |